Reaction

Renal Cell Carcinoma reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,869 reports · 92 co-occurring drugs

As of the last recalculation, Renal Cell Carcinoma appears in 4,869 FAERS reports alongside 92 co-occurring drug terms. The strongest observed disproportionality signal is SUNITINIB MALATE (PRR 132.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Sunitinib Malate	975	132.3	135.7
Sorafenib	273	59.5	60.3
Axitinib	244	56.3	57.0
Cabozantinib	506	50.1	50.7
Pazopanib Hydrochloride	277	46.3	46.8
Basiliximab	57	21.0	21.1
Everolimus Tablets	64	16.5	16.6
Everolimus	180	15.7	15.7
Lenvatinib	62	8.2	8.2
Mometasone	32	7.5	7.5
Cimetidine	16	7.1	7.1
Alemtuzumab	32	7.1	7.1
Melphalan	37	7.0	7.0
Melphalan Hydrochloride	38	6.5	6.5
Valsartan Oral	80	6.4	6.4
Azathioprine	113	5.6	5.6
Testosterone	30	5.5	5.5
Mycophenolate Mofetil	162	5.2	5.2
Mycophenolate Mofetil Hydrochloride	162	5.2	5.2
Tacrolimus Ointment 0.1%	148	5.2	5.2
Tacrolimus Extended-Release Capsules	148	5.2	5.2
Nivolumab	113	5.1	5.1
Lisinopril And Hydrochlorothiazide Tablets	9	4.9	4.9
Valsartan	117	4.9	4.9
Meperidine Hydrochloride	10	4.6	4.7
Sirolimus	14	4.5	4.5
Tacrolimus	158	4.4	4.4
Amlodipine Besylate And Valsartan	11	4.3	4.3
Isosorbide Dinitrate	19	4.2	4.2
Amlodipine Besylate	137	4.1	4.1
Enalapril Maleate	22	3.8	3.8
Lisinopril And Hydrochlorothiazide	9	3.8	3.8
Enalapril	48	3.7	3.7
Adalimumab-Fkjp	40	3.7	3.7
Adalimumab-Aaty	40	3.6	3.6
Bendamustine Hcl	13	3.6	3.6
Baricitinib	8	3.6	3.6
Polatuzumab Vedotin	8	3.5	3.5
Fludarabine Phosphate	32	3.5	3.5
Magnesium Oxide	34	3.5	3.5
Adalimumab-Adaz	42	3.4	3.4
Gemfibrozil	12	3.4	3.4
Terazosin Hydrochloride	7	3.4	3.4
Cyclosporine	85	3.3	3.3
Cefazolin	7	3.3	3.3
Midazolam	19	3.2	3.2
Labetalol	10	3.2	3.2
Prednisolone	130	3.1	3.1
Prednisolone Oral	130	3.1	3.1
Prednisolone Oral Solution	130	3.1	3.1
Mycophenilic Acid	15	3.1	3.1
Ezetimibe And Simvastatin	11	3.1	3.1
Midazolam Hydrochloride	19	3.0	3.0
Emtricitabine And Tenofovir Alafenamide	8	3.0	3.0
Tofacitinib Citrate	9	2.9	2.9
Metoclopramide	37	2.9	2.9
Ranitidine Hydrochloride	36	2.8	2.8
Metoclopramide Hydrochloride	51	2.8	2.8
Valsartan And Hydrochlorothiazide	9	2.8	2.8
Haloperidol	16	2.8	2.8
Haloperidol Lactate	16	2.8	2.8
Metoprolol Succinate Er Tablets	40	2.8	2.8
Cyclophosphamide Injection, Solution	110	2.7	2.7
Cyclophosphamide	110	2.7	2.7
Cyclophosphamide For Injection	110	2.7	2.7
Amlodipine	165	2.7	2.7
Prochlorperazine	17	2.6	2.6
Imatinib Mesylate	17	2.6	2.6
Entecavir	7	2.6	2.6
Insulin Human	23	2.5	2.5
Infliximab	122	2.4	2.4
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	5	2.4	2.4
Pioglitazone	23	2.3	2.3
Guanfacine	4	2.2	2.2
Thalidomide	18	2.1	2.1
Darbepoetin Alfa	26	2.1	2.1
Ranitidine	83	1.8	1.8
Acalabrutinib	5	1.8	1.8
Doxorubicin	36	1.7	1.7
Tenofovir Disoproxil Fumarate	13	1.7	1.7
Oxycodone Hydrochloride	83	1.6	1.6
Liraglutide	17	1.5	1.5
Ustekinumab	32	1.3	1.3
Emtricitabine And Tenofovir Disoproxil Fumarate	14	1.3	1.3
Ipilimumab	13	1.3	1.3
Methoxy Polyethylene Glycol-Epoetin Beta	3	1.2	1.2
Ixekizumab	10	1.2	1.2
Exenatide	14	1.1	1.1
Natalizumab	40	0.9	0.9
Guselkumab	7	0.8	0.8
Lenalidomide	80	0.8	0.8
Cinacalcet Hydrochloride	7	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.